वेनलाफैक्सिन के इंटरैक्शन

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (आइवाब्राडिन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (वेनलाफैक्सिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (इलोपेरिडोन लेबल, दवाओं के इंटरैक्शन)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (एज़िथ्रोमाइसिन लेबल, चेतावनियां और सावधानियां)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (एडोक्साबैन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (एमियोडेरोन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (एम्फेटामाइन और डेक्सट्रोएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (ऑक्सालिप्लैटिन लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (ऑक्सीकोडोन लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ओलिसेरिडिन लेबल, दवाओं के इंटरैक्शन)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (कार्बामाज़ेपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (कोडीन लेबल, दवाओं के इंटरैक्शन)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

…drugs, ziprasidone is contraindicated: • in patients with a known history of QT prolongation (including congenital long QT syndrome) • in patients with recent acute myocardial infarction • in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. (ज़िप्रासिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (टेट्राबेनाज़िन लेबल, दवाओं के इंटरैक्शन)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (डोफेटिलाइड लेबल, चेतावनियां)

…(12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval >500 ms or… (ड्रोनेडेरोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (थायोरिडाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (पाज़ोपैनिब लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (पिमोज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (पेंटाज़ोसिन और नालोक्सोन लेबल, सावधानियां)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (पैरासिटामोल और कोडीन लेबल, सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (प्रोपाफेनोन लेबल, चेतावनियां और सावधानियां)

…prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. (प्रोमेथाज़िन लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (प्रोमेथाज़िन और कोडीन लेबल, दवाओं के इंटरैक्शन)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (फेंटानिल लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Drugs that Prolong the QT Interval : Avoid concomitant use. (फेनोबार्बिटोन लेबल, दवाओं के इंटरैक्शन)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (फॉस्कारनेट लेबल, दवाओं के इंटरैक्शन)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (फॉस्फोमाइसिन लेबल, दवाओं के इंटरैक्शन)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (फ्लुकोनाज़ोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (फ्लुमाज़ेनिल लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (बेलाडोना और ओपियम लेबल, दवाओं के इंटरैक्शन)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, दवाओं के इंटरैक्शन)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, दवाओं के इंटरैक्शन)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (ब्यूटॉर्फेनॉल लेबल, सावधानियां)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ब्यूप्रेनॉर्फिन लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (वेनलाफैक्सिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (मेटाक्सालोन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (मेथएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (मेथाडोन लेबल, चेतावनियां और सावधानियां)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (मॉर्फिन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (वेनलाफैक्सिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (रेमिफेंटानिल लेबल, चेतावनियां और सावधानियां)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (वेनलाफैक्सिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (लिसडेक्सएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (लेवॉर्फेनॉल लेबल, सावधानियां)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (लेवोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (लोपिनाविर और रिटोनाविर लेबल, चेतावनियां और सावधानियां)

LOREEV XR should not be used in such patients without adequate antidepressant therapy. (लोराज़ेपाम लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (वेपडेजेस्ट्रेंट लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (वेनलाफैक्सिन लेबल, बॉक्स्ड चेतावनी)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (सिप्रोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

सेंट जॉन्स वॉर्ट को एंटीडिप्रेसेंट और अन्य सेरोटोनर्जिक दवाओं के साथ लेने से सेरोटोनिन सिंड्रोम का जोखिम बढ़ता है। (NCCIH, St. John's Wort)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (वेनलाफैक्सिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (हाइड्रॉक्सीक्लोरोक्वीन लेबल, चेतावनियां और सावधानियां)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोकोडोन लेबल, दवाओं के इंटरैक्शन)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, सावधानियां)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोकोडोन और होमाट्रोपिन लेबल, दवाओं के इंटरैक्शन)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (आइसोप्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (आइसोफ्लुरेन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (आरफॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (आर्टिकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (इप्राट्रोपियम और सैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (एरिबुलिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (एस्ज़ोपिक्लोन लेबल, चेतावनियां और सावधानियां)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (कैरिसोप्रोडोल लेबल, चेतावनियां और सावधानियां)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (कोकेन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (क्लोनाज़ेपाम लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (क्लोराज़ेपेट लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (क्लोरोप्रोकेन लेबल, सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. (क्वेटियापिन लेबल, चेतावनियां और सावधानियां)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (गोसेरेलिन लेबल, चेतावनियां और सावधानियां)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (ग्लाइकोपाइरोलेट लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (जेफिटिनिब लेबल, दवाओं के इंटरैक्शन)

Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine. (ज़ेलेप्लॉन लेबल, दवाओं के इंटरैक्शन)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use [see Drug Interactions (7.1) ] . (ज़ोल्पिडेम लेबल, चेतावनियां और सावधानियां)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (टरब्यूटालिन लेबल, सावधानियां)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (टेमाज़ेपाम लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (टोरेमिफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (ट्रिप्टोरेलिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (डाइसाइक्लोमिन लेबल, दवाओं के इंटरैक्शन)

Diazepam Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (डेसफ्लुरेन लेबल, चेतावनियां और सावधानियां)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (डेस्मोप्रेसिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (डैरिडोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (ड्रोनाबिनोल लेबल, चेतावनियां और सावधानियां)

…cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (ड्रोपेरिडोल लेबल, चेतावनियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

…combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. (पैलिपेरिडोन लेबल, चेतावनियां और सावधानियां)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (पैसिरियोटाइड लेबल, दवाओं के इंटरैक्शन)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (पोनेसिमोड लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (प्राइमाक्वीन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (प्रिलोकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (फाइसोस्टिग्मिन लेबल, चेतावनियां और सावधानियां)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (फिनाइलएफ्रिन लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (फॉस्फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (फ्लुटिकासोन और सैल्मेटेरोल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (बिस्मथ सबसाइट्रेट, मेट्रोनिडाज़ोल और टेट्रासाइक्लिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (बुडेसोनाइड और फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (ब्यूपिवाकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (मेट्रोनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (मेथस्कोपोलामाइन लेबल, दवाओं के इंटरैक्शन)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (मेपिवाकेन लेबल, चेतावनियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (मॉक्सीफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (यूमेक्लिडिनियम और विलैंटेरोल लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (रिफापेंटिन लेबल, दवाओं के इंटरैक्शन)

…5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (रिफैम्पिसिन लेबल, दवाओं के इंटरैक्शन)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (रिल्पिविरिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (रोक्यूरोनियम लेबल, चेतावनियां और सावधानियां)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (लिडोकेन लेबल, दवाओं के इंटरैक्शन)

…Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (लिडोकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (लियोथायरोनिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (लुमाटेपेरोन लेबल, चेतावनियां और सावधानियां)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (लेवोथायरोक्सिन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (लेवोसैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (ल्यूप्रोलाइड लेबल, चेतावनियां और सावधानियां)

Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (ल्यूरासिडोन लेबल, चेतावनियां और सावधानियां)

Patients receiving warfarin therapy should be carefully monitored when Venlafaxine Extended-Release Tablets are initiated or discontinued [see Warnings and Precautions ( 5.13 )] . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (वैसोप्रेसिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (सल्फामेथॉक्साज़ोल और ट्राइमेथोप्रिम लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (सुनिटिनिब लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (सेवोफ्लुरेन लेबल, चेतावनियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (सैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (सैल्मेटेरोल लेबल, दवाओं के इंटरैक्शन)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (सोटालोल लेबल, दवाओं के इंटरैक्शन)

The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (सोडियम ऑक्सीबेट लेबल, चेतावनियां और सावधानियां)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (सोराफेनिब लेबल, चेतावनियां और सावधानियां)

Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (स्कोपोलामाइन (हायोसिन) लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

Haloperidol: Increase in Haloperidol AUC and C max . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (कार्बिडोपा लेबल, दवाओं के इंटरैक्शन)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

…placebo-controlled trials of adult patients with major depressive disorder, the proportion of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) was greatest in the VRAYLAR 3 mg per day + antidepressant therapy arm (3.2%) compared with those taking VRAYLAR 1.5 mg per day + antidepressant therapy (2%) or those placebo-treated (1.3%). (कैरिप्राज़िन लेबल, चेतावनियां और सावधानियां)

Postmarketing Spontaneous Drug Interaction Reports There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (टियागाबिन लेबल, चेतावनियां)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (डाइवैल्प्रोएक्स (वैल्प्रोएट) लेबल, दवाओं के इंटरैक्शन)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (परफेनाज़िन लेबल, दवाओं के इंटरैक्शन)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (बेंज़ट्रोपिन लेबल, चेतावनियां)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (लोवास्टेटिन लेबल, चेतावनियां)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (वैल्प्रोइक एसिड लेबल, दवाओं के इंटरैक्शन)

Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

…quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone,… (हाइड्रॉक्सीज़िन लेबल, सावधानियां)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (एंटाकैपोन लेबल, सावधानियां)

In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin), or CYP3A4 (e.g., dextromethorphan) when coadministered with ABILIFY MAINTENA. (एरिपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (रोपिनिरोल लेबल, दवाओं के इंटरैक्शन)